| Comprehensive analysis of hypermutation in human cancer BB Campbell, N Light, D Fabrizio, M Zatzman, F Fuligni, R de Borja, ... Cell 171 (5), 1042-1056. e10, 2017 | 687 | 2017 |
| Longitudinal molecular trajectories of diffuse glioma in adults FP Barthel, KC Johnson, FS Varn, AD Moskalik, G Tanner, E Kocakavuk, ... Nature 576 (7785), 112-120, 2019 | 387 | 2019 |
| Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC FJ Swartling, V Savov, AI Persson, J Chen, CS Hackett, PA Northcott, ... Cancer cell 21 (5), 601-613, 2012 | 237 | 2012 |
| Pleiotropic role for MYCN in medulloblastoma FJ Swartling, MR Grimmer, CS Hackett, PA Northcott, QW Fan, ... Genes & development 24 (10), 1059-1072, 2010 | 219 | 2010 |
| Temozolomide-associated hypermutation in gliomas S Choi, Y Yu, MR Grimmer, M Wahl, SM Chang, JF Costello Neuro-oncology 20 (10), 1300-1309, 2018 | 173 | 2018 |
| Childhood tumors of the nervous system as disorders of normal development MR Grimmer, WA Weiss Current opinion in pediatrics 18 (6), 634-638, 2006 | 156 | 2006 |
| Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma YH Chanthery, WC Gustafson, M Itsara, A Persson, CS Hackett, ... Science translational medicine 4 (115), 115ra3-115ra3, 2012 | 101 | 2012 |
| Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction L Chesler, DD Goldenberg, R Collins, M Grimmer, GE Kim, T Tihan, ... Neoplasia 10 (11), 1268-IN34, 2008 | 78 | 2008 |
| Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation MR Grimmer, S Stolzenburg, E Ford, R Lister, P Blancafort, PJ Farnham Nucleic acids research 42 (16), 10856-10868, 2014 | 73 | 2014 |
| Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma L Chesler, DD Goldenberg, IT Seales, R Satchi-Fainaro, M Grimmer, ... Cancer research 67 (19), 9435-9442, 2007 | 73 | 2007 |
| Antibody targeting of E3 ubiquitin ligases for receptor degradation H Marei, WTK Tsai, YS Kee, K Ruiz, J He, C Cox, T Sun, S Penikalapati, ... Nature 610 (7930), 182-189, 2022 | 71 | 2022 |
| MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence R Mathur, Y Zhang, MR Grimmer, C Hong, M Zhang, S Bollam, K Petrecca, ... Neuro-oncology 22 (11), 1580-1590, 2020 | 63 | 2020 |
| Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas Y Yu, J Villanueva-Meyer, MR Grimmer, S Hilz, DA Solomon, S Choi, ... Neuro-oncology 23 (11), 1872-1884, 2021 | 54 | 2021 |
| Frequent lack of repressive capacity of promoter DNA methylation identified through genome-wide epigenomic manipulation E Ford, MR Grimmer, S Stolzenburg, O Bogdanovic, A Mendoza, ... biorxiv, 170506, 2017 | 52 | 2017 |
| BMPs oppose Math1 in cerebellar development and in medulloblastoma MR Grimmer, WA Weiss Genes & development 22 (6), 693-699, 2008 | 45 | 2008 |
| Large-scale manipulation of promoter DNA methylation reveals context-specific transcriptional responses and stability A de Mendoza, TV Nguyen, E Ford, D Poppe, S Buckberry, J Pflueger, ... Genome Biology 23 (1), 163, 2022 | 42 | 2022 |
| Effects on the transcriptome upon deletion of a distal element cannot be predicted by the size of the H3K27Ac peak in human cells YG Tak, Y Hung, L Yao, MR Grimmer, A Do, MS Bhakta, H O'Geen, ... Nucleic acids research 44 (9), 4123-4133, 2016 | 40 | 2016 |
| Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers J Cantley, X Ye, E Rousseau, T Januario, BD Hamman, CM Rose, ... Nature Communications 13 (1), 6814, 2022 | 35 | 2022 |
| Downregulation of MYCN through PI3K inhibition in mouse models of pediatric neural cancer TA Cage, Y Chanthery, L Chesler, M Grimmer, Z Knight, K Shokat, ... Frontiers in oncology 5, 111, 2015 | 35 | 2015 |
| Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma LE Jones, S Hilz, MR Grimmer, T Mazor, C Najac, J Mukherjee, ... Neuro-oncology advances 2 (1), vdaa088, 2020 | 26 | 2020 |
Louis CheslerUCSF, ICR, RMHVerified email at icr.ac.uk
